Document is current

Documents that mention this clinical trial

Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1

What is the role of surgery in potentially resectable N2 non-small cell lung cancer?
https://doi.org/10.1136/thoraxjnl-2018-212287

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8520

Documents that mention this clinical trial

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis
https://doi.org/10.1136/bmj-2021-067745

Documents that mention this clinical trial

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba8035

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
https://doi.org/10.1200/jco.2023.41.16_suppl.8522

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
https://doi.org/10.1200/jco-24-01681

Documents that mention this clinical trial

Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
https://doi.org/10.1200/jco-25-01828

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

Documents that mention this clinical trial

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3

1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
https://doi.org/10.1200/jco.22.01503

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Documents that mention this clinical trial

1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
https://doi.org/10.1200/jco.2024.42.16_suppl.8560

Tracking the tail
https://doi.org/10.1136/jitc-2020-000971

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
https://doi.org/10.1136/jitc-2023-008189

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9023

Documents that mention this clinical trial

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception
https://doi.org/10.1136/jitc-2025-012066

Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)
https://doi.org/10.1136/jclinpath-2021-207789